These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31155409)

  • 1. Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.
    Salhotra A; Afkhami M; Yang D; Mokhtari S; Telatar M; Gu D; Pillai RK; Weisenburger DD; Murata-Collins J; Weigel D; Aoun P; Aldoss I; Al Malki MM; Khaled S; Mei M; Ali H; Aribi A; Budde E; Sandhu K; O'Donnell M; Snyder D; Pullarkat V; Forman SJ; Marcucci G; Nakamura R; Stein A
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e400-e405. PubMed ID: 31155409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
    Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
    Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
    J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
    Ambinder A; Smith M; Tsai HL; Varadhan R; DeZern A; Dalton W; Gocke C; Webster J; Gondek L; Gojo I; Ali SA; Huff CA; Swinnen L; Wagner-Johnston N; Showel M; Prince G; Borrello I; Bolaños-Meade J; Luznik L; Jain T; Imus P; Fuchs E; Ambinder R; Gladstone DE; Levis M; Jones R; Ghiaur G; Smith BD
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):260-269. PubMed ID: 34750086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
    Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
    Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
    Duchmann M; Micol JB; Duployez N; Raffoux E; Thomas X; Marolleau JP; Braun T; Adès L; Chantepie S; Lemasle E; Berthon C; Malfuson JV; Pautas C; Lambert J; Boissel N; Celli-Lebras K; Caillot D; Turlure P; Vey N; Pigneux A; Recher C; Terré C; Gardin C; Itzykson R; Preudhomme C; Dombret H; de Botton S
    Blood; 2021 May; 137(20):2827-2837. PubMed ID: 33881523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
    Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
    Bill M; Jentzsch M; Bischof L; Kohlschmidt J; Grimm J; Schmalbrock LK; Backhaus D; Brauer D; Goldmann K; Franke GN; Vucinic V; Niederwieser D; Mims AS; Platzbecker U; Eisfeld AK; Schwind S
    Blood Adv; 2023 Feb; 7(3):436-444. PubMed ID: 35381077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
    DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
    Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent
    Ravindra N; Dillon LW; Gui G; Smith M; Gondek LP; Jones RJ; Corner A; Hourigan CS; Ambinder AJ
    medRxiv; 2023 Aug; ():. PubMed ID: 37662423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
    Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
    Balss J; Thiede C; Bochtler T; Okun JG; Saadati M; Benner A; Pusch S; Ehninger G; Schaich M; Ho AD; von Deimling A; Krämer A; Heilig CE
    Leukemia; 2016 Apr; 30(4):782-8. PubMed ID: 26582645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT.
    Mohty R; Bazarbachi AH; Labopin M; Esteve J; Kröger N; Cornelissen JJ; Blaise D; Socié G; Maury S; Ganser A; Gedde-Dahl T; von dem Borne P; Bourhis JH; Bulabois CE; Yakoub-Agha I; Pabst C; Nguyen S; Chevallier P; Huynh A; Bazarbachi A; Nagler A; Ciceri F; Mohty M
    Bone Marrow Transplant; 2024 Nov; 59(11):1534-1541. PubMed ID: 39143183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
    DiNardo CD; Propert KJ; Loren AW; Paietta E; Sun Z; Levine RL; Straley KS; Yen K; Patel JP; Agresta S; Abdel-Wahab O; Perl AE; Litzow MR; Rowe JM; Lazarus HM; Fernandez HF; Margolis DJ; Tallman MS; Luger SM; Carroll M
    Blood; 2013 Jun; 121(24):4917-24. PubMed ID: 23641016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of IDH mutations in acute myeloid leukemia.
    Montalban-Bravo G; DiNardo CD
    Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase mutations in myeloid malignancies.
    Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
    Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.